NASDAQ:NYMX - Nymox Pharmaceutical Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.89 +0.64 (+19.69 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$3.25
Today's Range$3.11 - $3.90
52-Week Range$3.00 - $4.69
Volume660,900 shs
Average Volume151,709 shs
Market Capitalization$178.49 million
P/E RatioN/A
Dividend YieldN/A
Beta0.71
Nymox Pharmaceutical logoNymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207) that has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia; and is in Phase II clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.

Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for NYMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NYMX
CUSIPN/A
Phone800-936-9669

Debt

Debt-to-Equity RatioN/A
Current Ratio0.47
Quick Ratio0.46

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$220,000.00
Price / Sales1,011.58
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-194.50

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-13,420,000.00
Net Margins-4,471.04%
Return on EquityN/A
Return on Assets-1,053.89%

Miscellaneous

Employees6
Outstanding Shares57,210,000

Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Corp (NASDAQ:NYMX) released its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.05) EPS for the quarter. The biopharmaceutical company had revenue of $0.15 million for the quarter. View Nymox Pharmaceutical's Earnings History.

When is Nymox Pharmaceutical's next earnings date?

Nymox Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Nymox Pharmaceutical.

Who are some of Nymox Pharmaceutical's key competitors?

Who are Nymox Pharmaceutical's key executives?

Nymox Pharmaceutical's management team includes the folowing people:
  • Dr. Paul Averback, Founder, Chairman, CEO & Pres (Age 67)
  • Mr. Erik Danielsen, Chief Financial Officer (Age 55)
  • Mr. Randall J. Lanham, Gen. Counsel, Sec. & Director (Age 54)
  • Dr. Judith Fitzpatrick Ph.D., Exec. (Age 69)
  • Dr. Suresh Kalbag M.D., Director of CMC Operations

Has Nymox Pharmaceutical been receiving favorable news coverage?

News headlines about NYMX stock have trended somewhat positive on Friday, Accern reports. Accern rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Nymox Pharmaceutical earned a news sentiment score of 0.01 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 44.42 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.31%) and Wedbush Securities Inc. (0.43%). View Institutional Ownership Trends for Nymox Pharmaceutical.

Which institutional investors are selling Nymox Pharmaceutical stock?

NYMX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Nymox Pharmaceutical.

Which institutional investors are buying Nymox Pharmaceutical stock?

NYMX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc.. View Insider Buying and Selling for Nymox Pharmaceutical.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $3.89.

How big of a company is Nymox Pharmaceutical?

Nymox Pharmaceutical has a market capitalization of $178.49 million and generates $220,000.00 in revenue each year. Nymox Pharmaceutical employs 6 workers across the globe.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is 9900 CAVENDISH BLVD. SUITE 306, St.-Laurent A8, H4M 2V2. The biopharmaceutical company can be reached via phone at 800-936-9669 or via email at [email protected]


MarketBeat Community Rating for Nymox Pharmaceutical (NYMX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  70 (Vote Underperform)
Total Votes:  148
MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical and other stocks. Vote "Outperform" if you believe NYMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NYMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.